On the designated date, the International Biopharmaceutical Industry Innovation Beijing Forum opened in the Beijing Economic and Technological Development Zone (Beijing Yizhuang). This forum, closely aligned with the theme of "Cultivating New Productive Forces to Promote High-Quality Development in the Pharmaceutical and Health Industry," delved into key topics such as the coordinated development of the medical, healthcare, and pharmaceutical sectors, strategic deployment in cutting-edge industries, international cooperation in innovative drugs, and the research and evaluation of innovative medical devices. The forum featured over a hundred experts and scholars from around the world, who delivered a series of compelling keynote speeches and dialogues.

At the opening ceremony of the Yizhuang Conference, multinational pharmaceutical companies such as Eli Lilly, Merck, Pfizer, Bayer, AstraZeneca, Medtronic, Danaher, and Shanghai HuaYa Biotech announced their plans to establish new R&D and innovation projects in Beijing. According to the information from the opening ceremony, several of these companies will be located in the Beijing Medical Innovation Park in the Beijing Economic-Technological Development Area (Yizhuang), with multiple projects being first-time initiatives. The pharmaceutical companies involved are Eli Lilly, Pfizer, Bayer, AstraZeneca, Medtronic, and Shanghai HuaYa Biotech. Yizhuang, which holds a dominant position in Beijing's pharmaceutical and health industry, is seeing global pharmaceutical giants accelerate their strategic layout, contributing to innovation and R&D with "Yizhuang Wisdom."

At the opening ceremony, Beijing's "Service Package" was also distributed to enterprises. The "Service Package" includes butler-style service content covering policy support, industrial connection, local security, and more. According to relevant officials from the Beijing Economic-Technological Development Area, Beijing Yizhuang is continuously attracting the establishment of R&D centers or innovation centers of multinational pharmaceutical companies. Beijing Yizhuang will implement the requirements of Beijing's "Service Package," providing services in areas such as innovation project connection and project landing support, conducting face-to-face policy advocacy, and interpreting newly issued municipal policies quarterly, helping enterprises to timely obtain and understand favorable policies for businesses. Additionally, assistance will be provided in connecting enterprises with clinical institutions and offering clinical trial services. Furthermore, key products in Beijing will be included in the municipal list of innovative medical devices and drugs, with city-district collaboration, offering comprehensive and end-to-end services in preclinical research, clinical studies, review and approval, industrial landing, and hospital application, accelerating the process of product market entry.

To provide ample element resources for pharmaceutical innovation, this multinational pharmaceutical company has chosen to "settle down" here. With the establishment of the National Medical Products Administration Information Center on the 10th, the six major centers under the National Medical Products Administration, including the Center for Drug Evaluation, the Center for Food and Drug Inspection, the Center for Drug Evaluation (National Center for Drug Adverse Reaction Monitoring), the Center for Medical Device Evaluation, the Center for Administrative Affairs Acceptance Services and Complaint Reporting, and the Information Center (China Food and Drug Regulatory Data Center), have all been established in Beijing Yizhuang. Beijing Yizhuang has gathered regulatory resources, providing strong support in administrative approval and qualification certification for the high-quality development of the biotechnology and big health industries.

According to the relevant person in charge of the Beijing Economic and Technological Development Area, within a radius of one kilometer, the area covers the regulatory agencies, three Grade A hospitals, and top medical institutions. Relying on the profound biopharmaceutical industry foundation of Yizhuang and Daxing, it provides ample element resources for pharmaceutical innovation. Additionally, Beijing Yizhuang will allocate "government, industry, academia, research, medicine, finance, services" full-element resources, layout industry-education integration bases, research hospitals, introduce high-level industrial service institutions, build common technology platforms supporting industrial development, and create an innovation-friendly industrial ecosystem. Here, systematic advancements will be made in scientific and technological innovation, demonstration applications, and institutional mechanisms, integrating and implementing policy innovations from various sectors in areas such as regulation, intellectual property protection, centralized procurement of medical insurance, medical services, and human genetic resource management, forming an industrial policy system that aligns with international rules. It will also leverage the artificial intelligence + healthcare application base and the Beijing Data Infrastructure Pilot Zone to create an international data port, promote data export, and empower industrial development.